Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

Similar articles for PubMed (Select 24756011)

1.

Evaluation of tumor markers for the differential diagnosis of benign and malignant ascites.

Liu F, Kong X, Dou Q, Ye J, Xu D, Shang H, Xu K, Song Y.

Ann Hepatol. 2014 May-Jun;13(3):357-63.

2.

CEA, AFP and CA 19-9 analysis in peritoneal fluid to differentiate causes of ascites formation.

Kaleta EJ, Tolan NV, Ness KA, O'Kane D, Algeciras-Schimnich A.

Clin Biochem. 2013 Jun;46(9):814-8. doi: 10.1016/j.clinbiochem.2013.02.010. Epub 2013 Feb 27.

PMID:
23454392
4.

The importance of serum and ascites fluid alpha-fetoprotein, carcinoembryonic antigen, CA 19-9, and CA 15-3 levels in differential diagnosis of ascites etiology.

Sari R, Yildirim B, Sevinc A, Bahceci F, Hilmioglu F.

Hepatogastroenterology. 2001 Nov-Dec;48(42):1616-21.

PMID:
11813585
5.

Clinical value of tumour markers and serum-ascites albumin gradient in the diagnosis of malignancy-related ascites.

Chen SJ, Wang SS, Lu CW, Chao Y, Lee FY, Lee SD, Wu SL, Cherng KL, Lo KJ.

J Gastroenterol Hepatol. 1994 Jul-Aug;9(4):396-400.

PMID:
7948823
6.

How to increase the diagnostic value of malignancy-related ascites: discriminative ability of the ascitic tumour markers.

Tuzun Y, Yilmaz S, Dursun M, Canoruc F, Celik Y, Cil T, Boyraz T.

J Int Med Res. 2009 Jan-Feb;37(1):87-95.

PMID:
19215677
7.

The role of ascitic fluid viscosity in the differential diagnosis of ascites.

Gokturk HS, Demir M, Ozturk NA, Unler GK, Kulaksizoglu S, Kozanoglu I, Serin E, Yilmaz U.

Can J Gastroenterol. 2010 Apr;24(4):255-9.

8.

Correlation of tumour markers in ascitic fluid and serum: are measurements of ascitic tumour markers a futile attempt?

Tuzun Y, Celik Y, Bayan K, Yilmaz S, Dursun M, Canoruc F.

J Int Med Res. 2009 Jan-Feb;37(1):79-86.

PMID:
19215676
9.

Laminin concentration in ascites of patients with hepatic cirrhosis and peritoneal carcinomatosis.

Catarino RM, Lopes JD, Forones NM, Parise ER.

Braz J Med Biol Res. 2005 Feb;38(2):271-6. Epub 2005 Feb 15.

10.

Tumor markers in the diagnosis of malignant serous effusions.

Cascinu S, Del Ferro E, Barbanti I, Ligi M, Fedeli A, Catalano G.

Am J Clin Oncol. 1997 Jun;20(3):247-50.

PMID:
9167746
11.

Finding the cause of ascites. The importance of accurate fluid analysis.

Marshall JB.

Postgrad Med. 1988 Jun;83(8):189-90, 195-8.

PMID:
3375150
12.

[Ascitic fluid: the value of various biological tests in the differential diagnosis between cirrhotic and neoplastic ascites].

Ghilain JM, Henrion J, Schapira M, Majois F, Beauduin M, Heller FR.

Acta Gastroenterol Belg. 1990 Mar-Apr;53(2):168-79. French.

PMID:
2267897
13.

Ascitic fluid cholesterol in malignant and tubercular ascites.

Sood A, Garg R, Kumar R, Chhina RS, Arora S, Gupta R, Bhatia KL.

J Assoc Physicians India. 1995 Nov;43(11):745-7.

PMID:
8773030
14.

Usefulness of ascitic fluid cholesterol as a marker for malignant ascites.

Rana SV, Babu SG, Kocchar R.

Med Sci Monit. 2005 Mar;11(3):CR136-42.

PMID:
15735567
15.

[Carcinoembryonic antigen (CEA) in ascites].

Coenen C, Schmidt G, Wegener M, Wedmann B, Bauer KH, Ricken D.

Fortschr Med. 1991 Apr 30;109(13):280-2. German.

PMID:
2066045
16.

Value of combined detection of AFU and TCH in differential diagnosis between malignant and non-tuberculous benign ascites.

Zhang H, Li F, Wei Q, Zhu YF.

Med Oncol. 2011 Dec;28 Suppl 1:S670-4. doi: 10.1007/s12032-010-9731-9. Epub 2010 Nov 2.

PMID:
21042955
17.

Significance of serum and ascitic fluid C-reactive protein in differential diagnosis of benign and malignant ascites.

Yuksel I, Karaahmet F, Coskun Y, Kılıncalp S, Hamamci M, Akinci H, Ustun Y, Simsek Z, Erarslan E, Coban S.

Dig Dis Sci. 2014 Oct;59(10):2588-93. doi: 10.1007/s10620-014-3205-4. Epub 2014 May 18.

PMID:
24838501
18.

Role of serum-ascites albumin gradient in differential diagnosis of ascites.

Younas M, Sattar A, Hashim R, Ijaz A, Dilawar M, Manzoor SM, Ali A, Khan FA.

J Ayub Med Coll Abbottabad. 2012 Jul-Dec;24(3-4):97-9.

PMID:
24669623
19.

Use of a variety of biological parameters in distinguishing cirrhotic from malignant ascites.

Alexandrakis MG, Moschandrea J, Kyriakou DS, Alexandraki R, Kouroumalis E.

Int J Biol Markers. 2001 Jan-Mar;16(1):45-9.

PMID:
11288954
20.

(1)H NMR spectroscopy of ascitic fluid: discrimination between malignant and benign ascites and comparison of the results with conventional methods.

Bala L, Sharma A, Yellapa RK, Roy R, Choudhuri G, Khetrapal CL.

NMR Biomed. 2008 Jul;21(6):606-14. doi: 10.1002/nbm.1232.

PMID:
18205245
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk